Subtype-Specific Suppression of Shiga Toxin 2 Released from Escherichia coli upon Exposure to Protein Synthesis Inhibitors
Open Access
- 1 September 2008
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (9) , 2987-2991
Abstract
Shiga toxins (Stx) are important virulence factors in the pathogenesis of severe disease including hemolytic-uremic syndrome, caused by Stx-producing Escherichia coli (STEC). STEC strains increase the release of Stx in vitro following the addition of fluoroquinolones, whereas protein synthesis inhibitors previously have been reported to suppress the release of Stx. The amount of Stx released from wild-type STEC strains incubated with protein synthesis inhibitors was examined by a Vero cell cytotoxicity assay. The amounts released were compared to the Stx type (Stx1 or Stx2) and additionally to the individual subtypes and toxin variants of Stx2. In general, Stx2 release was suppressed significantly upon exposure to protein synthesis inhibitors at MICs, which was not observed in the case of Stx1. Also, the average amount of different Stx2 toxin variants released was suppressed to various levels ranging from 14.0% (Stx2-O157-EDL933) to 94.7% (Stx2d-O8-C466-01B). Clinical studies exploring protein synthesis inhibitors as future candidates for treatment of intestinal infections caused by Stx2-producing STEC should therefore include knowledge of the toxin variant in addition to the subtype.Keywords
This publication has 21 references indexed in Scilit:
- Subtyping Method for Escherichia coli Shiga Toxin (Verocytotoxin) 2 Variants and Correlations to Clinical ManifestationsJournal of Clinical Microbiology, 2007
- Induction of Shiga Toxin-Converting Prophage inEscherichia coliby High Hydrostatic PressureApplied and Environmental Microbiology, 2005
- Pathogenic Escherichia coliNature Reviews Microbiology, 2004
- One of Two Copies of the Gene for the Activatable Shiga Toxin Type 2d in Escherichia coli O91:H21 Strain B2F1 Is Associated with an Inducible BacteriophageInfection and Immunity, 2002
- Bacteriophage control of Shiga toxin 1 production and release by Escherichia coliMolecular Microbiology, 2002
- Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapyPediatric Nephrology, 2002
- Escherichia coliHarboring Shiga Toxin 2 Gene Variants: Frequency and Association with Clinical SymptomsThe Journal of Infectious Diseases, 2002
- Role for a Phage Promoter in Shiga Toxin 2 Expression from a Pathogenic Escherichia coli StrainJournal of Bacteriology, 2001
- Toxin Gene Expression by Shiga Toxin-Producing Escherichia coli: the Role of Antibiotics and the Bacterial SOS ResponseEmerging Infectious Diseases, 2000
- Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7Canadian Journal of Microbiology, 1999